Trial reportPsychological medicine2012
Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
Trial report in Psychological medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05866575 (Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation), which is not on this map. Cited by 186 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction of the Therapeutic Response in Depression Based on an Early Neuro-computational Modeling Assessment of Motivation
Who cites it
186 citing papers in PubMed, 6 syntheses or guidelines pooled it, 417 citations in OpenAlex.
- Common and disorder-specific aberrant activation during reward and loss processing in major depressive disorder and addiction: a meta-analysis of fMRI studies.Molecular psychiatry · 2026Pooled it
- The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.CNS drugs · 2023Pooled it
- Diminished reward responsiveness is associated with lower reward network GluCEST: an ultra-high field glutamate imaging study.Molecular psychiatry · 2021Pooled it
- Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression.Cognitive, affective & behavioral neuroscience · 2020Pooled it
- Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis.The British journal of psychiatry : the journal of mental science · 2019Pooled it
- Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies.The American journal of psychiatry · 2013Pooled it
- Investigating the effect of increased dopamine signaling on cerebral blood flow in Major Depressive Disorder: a double-blind randomized placebo-controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Predicting Cognitive Change During Treatment for Inpatient Depression: Secondary Analysis From a Randomized Controlled Trial.Acta psychiatrica Scandinavica · 2026Trial
- Behavioral and electrophysiological evidence of reward processing deficits in repetitive negative thinking: Implications for depression.Psychological medicine · 2026Trial
- Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.Journal of affective disorders · 2025Trial
- A comparison between rTMS and antidepressant medication on depressive symptom clusters in treatment-resistant depression.European archives of psychiatry and clinical neuroscience · 2025Trial
- Impact of Activation Therapy for Inpatients With Major Depression: Primary and Secondary Outcomes From a Randomised Controlled Trial.Bipolar disorders · 2025Trial
- Effect of DLPFC rTMS on anhedonia and alpha asymmetry in depressed patients.Scientific reports · 2025Trial
- Bridge Nodes Linking Depression and Medication Taking Self-Efficacy Dimensions Among Persons With HIV: A Secondary Data Analysis.AIDS and behavior · 2025Trial
- Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.Psychiatry and clinical neurosciences · 2024Trial
- A parallel-arm, randomized trial of Behavioral Activation Therapy for anhedonia versus mindfulness-based cognitive therapy for adults with anhedonia.Behaviour research and therapy · 2024Trial
- Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Distorted thoughts as a mediator of depressive symptoms in patients with major depressive disorder: a longitudinal study.Health and quality of life outcomes · 2023Trial
- Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial.Translational psychiatry · 2022Trial
- Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.Molecular psychiatry · 2021Trial
126 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 8 countries.
Funding
Abstract
backgroundSymptom dimensions have not yet been comprehensively tested as predictors of the substantial heterogeneity in outcomes of antidepressant treatment in major depressive disorder.
methodWe tested nine symptom dimensions derived from a previously published factor analysis of depression rating scales as predictors of outcome in 811 adults with moderate to severe depression treated with flexibly dosed escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP). The effects of symptom dimensions were tested in mixed-effect regression models that controlled for overall initial depression severity, age, sex and recruitment centre. Significant results were tested for replicability in 3637 adult out-patients with non-psychotic major depression treated with citalopram in level I of Sequenced Treatment Alternatives to Relieve Depression (STAR*D).
resultsThe interest-activity symptom dimension (reflecting low interest, reduced activity, indecisiveness and lack of enjoyment) at baseline strongly predicted poor treatment outcome in GENDEP, irrespective of overall depression severity, antidepressant type and outcome measure used. The prediction of poor treatment outcome by the interest-activity dimension was robustly replicated in STAR*D, independent of a comprehensive list of baseline covariates.
conclusionsLoss of interest, diminished activity and inability to make decisions predict poor outcome of antidepressant treatment even after adjustment for overall depression severity and other clinical covariates. The prominence of such symptoms may require additional treatment strategies and should be accounted for in future investigations of antidepressant response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.